Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
Clinical trial NCT03884192 · UNKNOWN
Trial details
- NCT number
- NCT03884192
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-12
- Primary completion
- 2020-12-30
- Enrollment
- 162
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.